Cite
HARVARD Citation
Humby, F. et al. (2021). Rituximab versus tocilizumab in anti-TNF inadequate responder patients with rheumatoid arthritis (R4RA): 16-week outcomes of a stratified, biopsy-driven, multicentre, open-label, phase 4 randomised controlled trial. Lancet. 397 (10271), pp. 305-317. [Online].